M
MeMed Diagnostics
Developing breakthrough diagnostic solutions that empower physicians to make faster, better-informed treatment decisions
About MeMed Diagnostics
MeMed is a healthcare technology startup that operates in the medical diagnostics market. The company has developed a unique technology that can accurately distinguish between bacterial and viral infections in just 15 minutes. This is a significant advancement in the field, as these types of infections are often clinically indistinguishable, leading to incorrect treatment and misuse of antibiotics. MeMed's technology is based on two key products: MeMed BV®, the first FDA-cleared host-immune response assay, and MeMed Key®, a compact immunoassay platform that enables quick, sensitive protein measurements.
Read full description
The company's primary clients are physicians and healthcare providers who manage patients with acute infections. By using MeMed's technology, these professionals can make more informed decisions about patient treatment, potentially improving patient outcomes and reducing unnecessary antibiotic use.
MeMed's business model is likely based on selling its diagnostic products to healthcare providers and potentially charging for ongoing usage or services. The company's technology has been validated in multinational, double-blind clinical studies involving over 20,000 subjects in Europe, Israel, and the United States, demonstrating its effectiveness across different clinical settings and patient groups.
At a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Tirat Karmel, Israel
- Employees
- 101
- Open positions
- 6
- Dealroom signal
- 66.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Biotechnology, Decision Making, Infections and Infectious Diseases, Patient Care, Inflammatory Diseases, Core AI
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jan 2026 | $2M | — | The Israel Innovation Authority | ↗ |
| LATE VCOther financing | Jan 2022 | $93M | $372M | Social Capital · Caesarea Medical Electronics · The Phoenix Company · Clal Insurance | ↗ |
Growth signals
Latest recorded traffic for MeMed Diagnostics is 6.6K monthly website visits, down 5.7% over the last three months. MeMed Diagnostics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
European Innovation Council- HIHorizon 2020 FTI (Fast Track to Innovation)
Congressionally Directed Medical Research Programs
European Commission
The Israel Innovation Authority
Series A1 investor entered at this stage
Series B and later15 investors entered at this stage
Caesarea Medical Electronics
Li Ka-shing
Ping An Ventures
Horizons Ventures
OurCrowd
Foxconn Technology Group
The Phoenix Company
Clal Insurance
WTI
La Maison Partners- TCTouchwood Capital
Western Technology Investment
Poalim Capital Markets
Shavit Capital
Union Tech Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MeMed Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MeMed Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.